loader2
Partner With Us NRI

FDC Ltd share Price Today

Company details

423.35
432.50
249.25
487.70
6M Return 10.81%
1Y Return 66.76%
Mkt Cap.(Cr) 6,917.80
Volume 114,410
Div Yield 0.00%
OI
-
OI Chg %
-
Volume 114,410

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500

Pharmaceuticals company FDC announced Q2FY24 & H1FY24 results:

  • Q2FY24:
    • Operating Revenue: Rs 486 crore, a solid 9.3% YoY growth.
    • EBITDA: Rs 76 crore, up by 13.5% YoY.
    • EBITDA Margin: 15.2%.
    • PBT: Rs 93 crore, a notable 34.3% YoY increase.
    • PAT: Rs 70 crore, showing a strong 34.7% YoY growth.
    • EPS: Rs 4.22, with a significant 36.2% YoY increase.
  • H1FY24:
    • Operating Revenue: Rs 1,023 crore, an 8.8% YoY growth.
    • EBITDA: Rs 198 crore, a substantial 36.5% YoY increase.
    • EBITDA Margin: 19.4%.
    • PBT: Rs 233 crore, with a remarkable 49.6% YoY growth.
    • PAT: Rs 180 crore, showing a notable 46.7% YoY increase.
    • EPS: Rs 10.84, with a strong 47.5% YoY growth.

Commenting on the results, the company said, "During Q2FY24 and H1FY24, we are pleased to announce that we have achieved growth across all our business segments in Domestic as well as International business. The major driver growth in the Domestic Formulation business is laid by the flagship brands, Electral, Zifi, Enerzal and Zifi-O. Growth in the International Formulation business is primarily laid by the US market growing by 31.7% during H1FY24. Further, the margins and profitability have shown significant improvements during the quarter as well as H1FY24 attributable primarily to improved sale realisation, lower cost of goods sold, and lower operating expenses."

 

 

Result PDF

View Other Company Results

FDC Ltd shares SWOT Analysis

Strengths (8)

  • Company with high TTM EPS Growth
  • Companies with rising net profit margins - quarterly as well as TTM basis
  • Growth in Net Profit with increasing Profit Margin (QoQ)

Weakness (8)

  • MFs decreased their shareholding last quarter
  • Inefficient use of capital to generate profits - RoCE declining in the last 2 years
  • Inefficient use of shareholder funds - ROE declining in the last 2 years

Opportunity (0)

Data not found

Threats (2)

  • Companies with growing costs YoY for long term projects
  • RSI indicating price weakness

Resistance and support

R1 430.5
R2 436.1
R3 439.6
Pivot

426.92

S1 421.3
S2 417.8
S3 412.2
EMA SMA
434.2
432.5
418.4
390.1
436.5
438.1
417.9
388.7
Delivery and volume
CLIENT NAME DEAL TYPE ACTION DATE AVG. PRICE QUANTITY EXCHANGE
AMEYA FAMILY DISCRETIONARY TRUST Bulk Purchase 2017-03-28 203.55 16134016 BSE
ADITI FAMILY DISCRETIONARY TRUST Bulk Purchase 2017-03-28 203.55 10756110 BSE
ASHOK ANAND CHANDAVARKAR Bulk Sell 2017-03-28 203.55 16134016 BSE
Name Category Shares
MEERA RAMDAS CHANDAVARKAR PROMOTER 19.44%
NANDAN MOHAN CHANDAVARKAR (IN THE CAPACITY OF TRUSTEE OF SANDHYA MOHAN CHANDAVARKAR TRUST) PROMOTER 11.01%
NANDAN MOHAN CHANDAVARKAR (IN THE CAPACITY OF TRUSTEE OF MOHAN ANAND CHANDAVARKAR TRUST) PROMOTER 10.81%
AMEYA ASHOK CHANDAVARKAR PROMOTER 6.1%
NOMITA R CHANDAVARKAR PROMOTER 3.23%
NANDAN MOHAN CHANDAVARKAR PROMOTER 3.1%
ADITI C BHANOT PROMOTER 0.68%
LEO ADVISORS PVT LTD PROMOTER 9.17%
VIRGO ADVISORS PVT LTD PROMOTER 6.12%

FINANCIALS

Sales
Operating Profit
Profit after Tax
Equity
Reserves and Surplus
Debt
Sales
Operating Profit
Profit after Tax
PE
Debt/Equity
P BV

FDC Ltd Stocks COMPARISON

Financials( in Cr) FDC Ltd Sun Pharmaceuticals Industries Ltd Cipla Ltd Dr Reddys Laboratories Ltd Zydus Lifesciences Ltd
Price 424.90 1,620.55 1,496.95 6,157.90 1,007.35
% Change 0.24 1.02 2.30 1.88 0.77
Mcap Cr 6,917.80 388,824.23 120,856.26 102,719.31 101,964.37
Revenue TTM Cr 1,783.75 43,885.68 15,790.60 24,669.70 17,237.40
Net Profit TTM Cr 193.83 8,560.84 2,513.47 4,507.30 1,997.30
PE TTM 23.86 41.45 30.52 19.64 30.51
1 Year Return 66.76 64.78 68.33 37.28 109.04
ROCE 13.04 16.79 14.76 25.99 16.25
ROE 9.84 16.46 10.66 21.21 14.05
INSIDER & INSTITUIONAL ACTIVITY

Equity Capital: 1,982.05 Cr FV: 1.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 29,068.81 33,709.58
LAST 3M 68,518.10 30,558.15
LAST 6M 130,081.93 64,349.19
LAST 12M 189,941.35 208,211.24

FDC Ltd Information

Stock PE (TTM)
23.86
Promoter Holding
69.66%
Book Value
121.1535
ROCE
13.04%
ROE
9.84%
Description
  • FDC Ltd. is an Indian company engaged in the business of pharmaceuticals. It initiated the concept of Oral Rehydration Salts (ORS) and is now a pioneer in the segment with its brand Electral. The company was founded in 1936, with its headquarters in Aurangabad, Maharashtra. During the June 2022 quarter, its total income was Rs 513.79 crore, up 46.49% from the previous March 2022 quarter. On 27 October 2022, FDC Ltd.’s market capitalisation stood at Rs 5,006 crore.

    The company is listed on the Bombay Stock Exchange with the code FDC and on the National Stock Exchange with the code 531599.

    FDC Ltd. manufactures and distributes a range of generics, formulations, and active pharmaceutical ingredients (API) at its manufacturing plants. It also produces functional foods and beverages. Pyrimon, Cotaryl, Zifi, Enerzal, Electral, Vitcofol, Zathrin, Zoxan, Zocon, Zefu, Mycoderm, and Zipod are some of the brands owned by the company.

    On 30 June 2022, FDC Ltd.’s shareholding pattern showed public holdings of 20.1%, domestic institutional investor holdings of 6.08%, foreign institutional investor holdings of 4.34%, and promoter holdings of 69.5%. Ms Meera Ramdas Chandavarkar is the leading promoter, with a 19.4% share.

    The company’s top management comprises Mr Ramdas A Chandavarkar, Mr Nandan M Chandavarkar, Mr Ashok A Chandavarkar, Dr Mahesh Bijlani, Mr Sanjay Jain, Mr Mohan A Chandavarkar, CA Uday Kumar Gurkar, Mr Ameya A Chandavarkar, Mr Melarkode Ganesan Parameswaran, Ms Nomita R Chandavarkar, CA Swati S Mayekar, Ms Varsharani Kate, and Ms Usha Athreya Chandrasekhar. The company’s auditors are B S R & Co. LLP. As of 30 June 2022, the company’s total number of outstanding shares was 16.59 crores.

    On 27 October 2022, the company’s share price was trending at Rs 301.95 on BSE and Rs 301.75 on NSE. The company’s highest share price in 52 weeks was Rs 345, and the lowest price was Rs 225. By investing in FDC Ltd.’s shares, investors earned a six-month return of 9.26% and a one-year return of -7.97%.

    As of September 2022, ICICI Prudential Pharma Healthcare and Diagnostics (P H D) Fund had a 3.21% stake in FDC Ltd. The company’s other mutual fund holdings include Tata India Pharma & Healthcare Fund, ITI Pharma and Healthcare Fund, and ICICI Prudential ESG Fund, with 2.39%, 1.93%, and 1.12% stakes, respectively.

    Disclaimer: ICICI Securities Ltd. (I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is a Member of National Stock Exchange of India Ltd (Member Code :07730), BSE Ltd (Member Code :103) and Member of Multi Commodity Exchange of India Ltd. (Member Code: 56250) and having SEBI registration no. INZ000183631. Name of the Compliance officer (broking): Mr. Anoop Goyal, Contact number: 022-40701000, E-mail address: complianceofficer@icicisecurities.com. Investment in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. The contents herein above are solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments or any other product. Investors should consult their financial advisers whether the product is suitable for them before taking any decision. The contents herein mentioned are solely for informational and educational purpose.

Registered Address

B-8 MIDC Industrial Area, Waluj Dist, Aurangabad (Maharashtra), Maharashtra, 431136

Tel : 91-240-2554407/967/299
Email : investors:fdcindia.com; waluj:fdcindia.com
Website : http://www.fdcindia.com
Registrar

Sharex Dynamic (India) Pvt Ltd

AGM Date (Month) : Sep
Face Value Equity Shares : 1
Market Lot Equity Shares : 1
BSE Code : 531599
NSE Code : FDC
Book Closure Date (Month) : Sep
BSE Group : A
ISIN : INE258B01022

FAQ’s on FDC Ltd Shares

You can buy FDC Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy FDC Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Mar 28, 2024 03:59 PM the closing price of FDC Ltd was ₹ 424.90.

Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of Mar 28, 2024 03:59 PM, the market cap of FDC Ltd stood at ₹ 6,917.80.

The latest PE ratio of FDC Ltd as of Mar 28, 2024 03:59 PM is 23.86

The latest PB ratio of FDC Ltd as of Mar 28, 2024 03:59 PM is 0.29

The 52-week high of FDC Ltd share price is ₹ 487.70 while the 52-week low is ₹ 249.25

Download Our

Download App
market app